Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

16.12 +0.66 (+4.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside ↗
Jefferies upgrades Instil Bio to "Buy" with a $52 target, anticipating significant growth for PD-(L)1xVEGF class and SYN2510's potential in cancer treatments. 
Via Benzinga
News headline image
Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Summit Therapeutics Inc.
Via Business Wire
News headline image
Prediction: These 3 Healthcare Stocks Will Soar in 2025 ↗
Via The Motley Fool
News headline image
3 Stocks That Could Be Monster Winners in 2025 ↗
Via The Motley Fool
News headline image
Where Will Summit Therapeutics Be in 5 Years? ↗
Via The Motley Fool
News headline image
How Is The Market Feeling About Summit Therapeutics? ↗
 
Via Benzinga
News headline image
Preview: Summit Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
3 Stocks That Could Turn $1,000 into $5,000 by 2030 ↗
Via The Motley Fool
News headline image
3 No-Brainer Biotech Stocks to Buy With $200 Right Now ↗
Via The Motley Fool
News headline image
2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall Street ↗
Via The Motley Fool
News headline image
Investing $5,000 in Each of These 3 Stocks at the Start of 2024 Would Have Created a Portfolio Worth More Than $100,000 Today ↗
Via The Motley Fool
News headline image
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
News headline image
Why Summit Therapeutics Stock Rocketed 6% Higher on Friday ↗
Via The Motley Fool
News headline image
Billionaire Ken Griffin Is Selling Palantir and Buying a Stock Wall Street Expects to Rocket 139% Higher ↗
Via The Motley Fool
News headline image
Warning: This Skyrocketing Stock Has a Hidden Risk ↗
Via The Motley Fool
News headline image
Summit Therapeutics to Present at Upcoming Investor Conferences
From Summit Therapeutics Inc.
Via Business Wire
News headline image
3 Monster Stocks in the Making ↗
Via The Motley Fool
News headline image
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
News headline image
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics ↗
Merck is spending up to $3.3 billion in a licensing deal for an anti-PD-1/VEGF drug from China. 
Via Investor's Business Daily
News headline image
BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential ↗
Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future revenue amid shifting company focus. 
Via Benzinga
News headline image
MarketBeat Week in Review – 11/4 - 11/8
Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts 
Via MarketBeat
Topics Economy Government
News headline image
2 Hot Biopharma Stocks to Buy and Hold for 5 Years ↗
If you're patient, these businesses have a lot of promising projects in the works. 
Via The Motley Fool
News headline image
Why Summit Therapeutics Stock Was a Winner Today ↗
A cancer drug has vast potential for the company, says a pundit newly following it. 
Via The Motley Fool
News headline image
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo ↗
JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 price target amid strong trial results. 
Via Benzinga
News headline image
Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Summit Therapeutics Inc. aims to advance Ivonescimab, a potential breakthrough for NSCLC. The FDA's Fast Track designation boosts its U.S. clinical pathway. 
Via MarketBeat
News headline image
This Tencent Music Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
3 Magnificent Stocks Under $100 to Buy in November ↗
The price could be right for these stocks. 
Via The Motley Fool
News headline image
2 Dividend Stocks to Buy for a Lifetime of Passive Income ↗
These are the kinds of stocks that can allow investors to sleep easy at night. 
Via The Motley Fool
News headline image
3 Stocks That Have Generated 1,000% Returns in Just 2 Years ↗
Should you add these fast-growing stocks to your portfolio? 
Via The Motley Fool
News headline image
Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024
From Summit Therapeutics Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.